In May 2026, the National Institute for Health and Care Excellence (NICE) published its first recommendations under the new digital health pathway.
Eight asthma self-management apps - Asthmahub, myAsthma, Digital Health Passport, and others - were approved for NHS use.
Two weeks later, NICE recommended AI-assisted echocardiography analysis for heart failure diagnosis and monitoring.
For the first time, the promise of the NHS 10-Year Health Plan is being translated into actual approvals for accelerated healthtech adoption.
However, approval, as it turns out, is not the same as adoption. A month into the rollout, the gap between what NICE recommended and what's actually available to patients reveals the real distance between policy intent and healthcare reality.
This is not a story about failure; the government's commitment is genuine, the approvals are real, the technologies work.
Rather, it's about what "approval" actually means when it comes to getting NHS innovation into the hands of patients, and what the gap suggests about the remaining barriers that no amount of policy reform has yet managed to overcome.
What NICE Technology Appraisal Actually Approved (And What It Doesn't Guarantee)
When NICE published the asthma guidance in May 2026, the language was confident.
Eight digital platforms were now approved to support asthma self-management, each one includes symptom tracking, medication reminders, educational content, and personalised action plans.
The technologies can be used in NHS care "during a three-year evidence generation period," after which NICE will decide whether to recommend them for routine, nationwide use.
Note that phrasing can be used during an evidence period.
This approach is not "must be implemented." It's not "NHS trusts will fund this."
It's a conditional approval - green light to proceed while gathering data.
The same pattern appears with the AI echocardiography guidance, published May 19.
NICE recommended AI-assisted echocardiography for early use to support diagnosis and monitoring of heart failure, with guidance that will be reviewed if new evidence emerges.
This is how NICE's new digital health pathway actually works, and it matters. The technologies are approved, but approval operates within a framework of measured caution.
NICE isn't saying "this is proven beyond question; implement immediately."
NICE is saying "this shows promise; use it while we collect more data; tell us what happens."
That distinction sounds technical. In practice, it shapes everything about what happens next.
The Approval-to-Adoption Gap
Since the NICE approvals in May, some movement has occurred in NHS healthtech adoption efforts. My mhealth announced national rollout of myAsthma Biologic in partnership with NHS hospitals, targeting support for 10,000 patients with severe asthma on biologic therapy.
A government partnership worth more than £10 million, the Respiratory Transformation Partnership - brings together NHS England, 15 health innovation networks, and pharmaceutical companies to use digital tools to improve asthma and COPD care, enabling community and primary care teams to support patients closer to home.
These are genuine commitments.
Real money. Named hospitals and services, but they're also selective.
MyAsthma Biologic targets severe asthma patients on biologic therapy which is a specific cohort, not universal rollout. The Respiratory Transformation Partnership is organised, but it's a partnership with specific players and specific funding, not a blanket mandate across the NHS.
Meanwhile, what about the other seven NICE-approved platforms? Asthmahub, Digital Health Passport, Luscii, RDMP, Smart Asthma, where are they?
The guidance says they can be used, yet barriers to NHS healthtech adoption persist.
One month after NICE approval, the answer to "Are patients in my region using these?" is: sometimes. It depends on local ICB strategy, on whether a trust has allocated funds, on whether a region has signed up for the Transformation Partnership.
The variation that plagues NHS procurement- different rules in different places, patchy coverage - persists even when NICE has given the green light.
This gap is the approval-to-adoption; NICE can approve.
NICE cannot mandate funding. NICE cannot enforce implementation.
Those powers sit elsewhere, fragmented across 42 Integrated Care Boards and individual NHS trusts operating under different budget constraints.
The Transformation Funding Puzzle
The 10-Year Plan promised 3% of NHS budgets - roughly £6 billion annually - reserved for transformation investments under NHS digital health policy.
The framing suggested ringfenced money, dedicated resources for innovation adoption.
Here's what the detailed guidance actually says: NHS organisations should reserve 3% of budgets for transformation. Transformation is broadly defined and includes digital infrastructure investment, internal process redesign, staff retraining, system integration work, and external technology adoption - key elements of NHS technology adoption strategy.
But it can also mean many other things. An ICB can allocate its 3% to redesigning internal workflows. Another can use it for staff development. A third can prioritise external innovation. The guidance is permissive, but the allocation is local.
More critically, it's discretionary, not guaranteed.
Each of the 42 Integrated Care Boards in England makes local decisions about how to deploy the funds, directly impacting NHS healthtech adoption across regions.
No framework saying: "Here's how innovators access this 3%." Instead, funding depends entirely on whether a region has made external technology adoption a strategic priority.
In practice, this creates variation. An ICB under budget pressure might allocate its 3% to internal digital projects with lower procurement friction. Another, more innovation-focused, might genuinely prioritise external healthtech. A third might use the money for both. The variation persists even within a supposedly standardised system.
For healthtech startups, the implication is uncomfortable. The 3% is real money.
But it's not guaranteed access. And accessing it depends on local ICB appetite, which is uneven across the country.
The MedTech Mandate Under Review
The third piece of the promised acceleration is the MedTech Funding Mandate - the oldest of the three mechanisms, launched in 2021. The Mandate is meant to be straightforward: NICE approves a cost-saving medical device or digital product. The policy then mandates that NHS commissioners must fund it when clinically appropriate. Financial barriers disappear. Adoption follows.
Except here's the contradiction at the heart of the mechanism: the Mandate doesn't provide new funding. Commissioners are required to buy NICE-approved medtech, but the money comes from existing budgets. If the barrier was financial, if trusts say they can't afford innovation, then a mandate to fund something from unchanged budgets doesn't actually remove the barrier. It shifts priority, but it doesn't add resources.
More tellingly, the Mandate is currently paused.
For 2025/26, only one technology - AposHealth, a device for knee osteoarthritis - was supported. For 2026/27, no new products are being added.
The policy sits under review. NHS England is reconsidering whether the Mandate, as structured, actually works.
Why? The guidance cites alignment with the 10-Year Health Plan and broader system needs. Translation: the department is questioning whether the mechanism achieves what it claims about supporting NHS healthtech adoption. After five years of operation with selective uptake, the government is asking whether mandating adoption without funding actually accelerates availability.
That question, hanging open since the review began, reveals something important about these three mechanisms. NICE can approve. The 3% can theoretically support adoption.
The Mandate can theoretically mandate it. But none of them add funding to a system already under severe financial strain. None of them guarantee that, even after approval, a technology actually reaches patients.
For startups, the Mandate's pause is a signal. The mechanism was supposed to be the safety net, the guarantee that, if you get approved, you'll reach scale. Instead, it's being reconsidered.
The Gap Between Approval and Access
So here's where the NHS health system sits in June 2026, NICE has done its job, the new NICE technology appraisal pathway is live, eight asthma apps are approved, and AI echocardiography is approved.
The process works. Technologies have been evaluated, criteria applied, recommendations made.
But NICE recommendation is not the same as NHS adoption. Approval is not the same as access. A month after the asthma guidance was published, some trusts are using myAsthma Biologic. Some regions have joined the Respiratory Transformation Partnership. But other approved platforms remain unused in many parts of the country. Some ICBs haven't yet integrated the NICE recommendations into their NHS technology adoption processes. Some clinicians aren't yet aware the guidance exists. Some trusts don't have budget allocated.
The government's three mechanisms - NICE appraisals, 3% transformation budgets, and the MedTech Mandate, are all operating as designed.
They're not broken, but they're also not sufficient to bridge the gap between approval and NHS healthtech adoption. NICE can evaluate technologies.
It cannot fund them. The 3% budgets exist, but their allocation is local and uneven.
The Mandate promises consideration, not guaranteed access.
What they collectively reveal is a system that has created a pathway to approval but hasn't yet created a pathway to scale. NICE technology appraisal processes are standardised. Adoption remains fragmented. A startup can now navigate NICE. But navigating the 42 different ICBs, with their different budgets, different priorities, and different procurement rules, remains the actual challenge.
For the healthtech companies watching the May NICE guidance, the reality of NHS healthtech adoption presents both opportunity and uncertainty. The pathway exists. Approval is achievable. But approval leads not to guaranteed adoption, but to a three-year evidence-gathering period followed by a new set of negotiations with local systems, each operating independently, each under financial pressure, each making local decisions about which innovations to prioritise.
This is the reality of reforming a system where policy can create pathways but cannot mandate resources.
The government can approve, but adoption belongs to the fragmented local structures that govern NHS procurement.
Where innovation and NHS reality remain, even now, operating on different timescales.
Sources
National Institute for Health and Care Excellence (NICE). "Digital platforms recommended to help people manage their asthma." January 7, 2026; National Institute for Health and Care Excellence (NICE). "AI-assisted echocardiography analysis and reporting for diagnosis and monitoring of heart failure." Technology Guidance HTG779, May 19, 2026; my mhealth. "My mhealth and their NHS partners announce the national rollout of myAsthma Biologic, a digital therapeutic designed to support patients with severe asthma." November 13, 2025; Digital Health. "£10m partnership will use digital tools to improve respiratory care." March 20, 2026; NHS England. "MedTech Funding Mandate Policy Guidance." May 2024 (updated 2025); Synopulse. "NICE backs digital asthma tools for NHS use as evidence builds." January 8, 2026; The Pharmaceutical Journal. "NICE recommends apps for use in asthma management." January 7, 2026; Health Service Journal. "Digital tools approved to support asthma patients." Multiple articles, January–March 2026; NHS England. "NHS 10-Year Health Plan." July 2025.
